Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New sedative may be safer for ICU patients on breathing machines

NCT ID NCT07536750

Symptom relief Sponsor: Nanfang Hospital, Southern Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at two sedatives, ciprofol and propofol, given to ICU patients who need breathing support but are not on a ventilator. The goal is to see which drug works better and causes fewer breathing problems. About 1,680 adults from 30 hospitals in China will be included, and researchers will review past medical records to compare the drugs' safety and effectiveness.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 1,680 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will consist of patients admitted to intensive care units at multiple tertiary hospitals in China, including Southern Medical University Nanfang Hospital. Eligible patients who meet the predefined inclusion and exclusion criteria will be enrolled in the study.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria Age: * Age ≥18 years * Admitted to the intensive care unit (ICU) between January 1, 2022 and July 30, 2024 * Received intravenous sedation with either ciprofol or propofol during ICU stay * Total duration of ciprofol or propofol administration ≥2 hours * Sedation initiated while the patient was not receiving invasive mechanical ventilation * Receiving non-invasive respiratory support or oxygen therapy at the time sedation was started, including noninvasive ventilation (NIV), high-flow nasal cannula (HFNC), nasal cannula, or face mask oxygen therapy * Availability of complete electronic medical records including sedation assessment using the Richmond Agitation-Sedation Scale (RASS) * Availability of continuous vital sign monitoring records including respiratory rate, oxygen saturation, blood pressure, and heart rate Exclusion Criteria: * Age \<18 years * Pregnancy or breastfeeding * Use of other primary sedative agents during the observation period, including midazolam or dexmedetomidine * Total exposure time to ciprofol or propofol \<2 hours * Known allergy or hypersensitivity to ciprofol, propofol, or their formulation components * Initiation of invasive mechanical ventilation before sedation * Missing key clinical data required for outcome evaluation, including sedation score, vital signs, or drug administration records * Participation in other interventional clinical trials that may interfere with outcome assessment * Severe visual or hearing impairment preventing accurate sedation assessment * Coma or conditions that prevent reliable evaluation using the Richmond Agitation-Sedation Scale (RASS) * Any condition that the investigators consider inappropriate for inclusion in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Critical illness are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Critical Illness respiratory failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Critical illness Respiratory failure

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Nanfang Hospital, Southern Medical University

    RECRUITING

    Guangzhou, Guangdong, 510515, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.